Ocular Therapeutix [OCUL] vs BridgeBio Pharma [BBIO] Detailed Stock Comparison

Ocular Therapeutix

NASDAQ

BridgeBio Pharma

NASDAQ

TLDR: Quick Comparison Summary

Based on 18 vital metrics comparison: Ocular Therapeutix wins in 6 metrics, BridgeBio Pharma wins in 12 metrics, with 0 ties. BridgeBio Pharma appears stronger overall.

View Metrics Details

Vital Metrics Comparison

Metric	Ocular Therapeutix	BridgeBio Pharma	Better
P/E Ratio (TTM)	-9.69	-17.12	BridgeBio Pharma
Price-to-Book Ratio	6.86	-5.28	BridgeBio Pharma
Debt-to-Equity Ratio	25.15	-1.04	BridgeBio Pharma
PEG Ratio	-0.19	-0.12	Ocular Therapeutix
EV/EBITDA	-7.70	-17.18	BridgeBio Pharma
Profit Margin (TTM)	91.17%	98.25%	BridgeBio Pharma
Operating Margin (TTM)	-502.57%	-120.72%	BridgeBio Pharma
Return on Equity	-63.41%	36.76%	BridgeBio Pharma
Return on Assets (TTM)	-31.14%	-41.96%	Ocular Therapeutix
Free Cash Flow (TTM)	$-135.97M	$-529.63M	Ocular Therapeutix
1-Year Return	35.02%	93.99%	BridgeBio Pharma
Price-to-Sales Ratio (TTM)	37.28	40.63	Ocular Therapeutix
Enterprise Value	$1.83B	$10.71B	BridgeBio Pharma
EV/Revenue Ratio	32.26	45.43	Ocular Therapeutix
Gross Profit Margin (TTM)	85.56%	96.70%	BridgeBio Pharma
Revenue per Share (TTM)	$0	$1	BridgeBio Pharma
Earnings per Share (Diluted)	$-1.26	$-4.13	Ocular Therapeutix
Beta (Stock Volatility)	1.49	1.23	BridgeBio Pharma

Performance

Key Stats

Valuation

Financials

Short Interest

Dividends

Ocular Therapeutix vs BridgeBio Pharma Stock Performance Analysis

Loading Price Chart...

Performance Comparison

Short-term Returns

Stock	1D	1W	1M	3M	6M	YTD
Ocular Therapeutix	1.40%	-2.54%	6.49%	70.36%	82.76%	40.73%
BridgeBio Pharma	-2.29%	-4.36%	7.23%	48.86%	35.39%	74.04%

Long-term Returns

Stock	1Y	3Y	5Y	10Y	15Y	20Y
Ocular Therapeutix	35.02%	142.13%	40.57%	-29.59%	-6.46%	-6.46%
BridgeBio Pharma	93.99%	368.51%	65.93%	82.05%	82.05%	82.05%

Performance Comparison

This comparison requires JavaScript for dynamic charts and real-time data. For complete performance analysis, visit the individual stock overview pages:

Ocular Therapeutix (OCUL): View Full Stock Overview

BridgeBio Pharma (BBIO): View Full Stock Overview

The individual stock overview pages contain detailed performance metrics, historical charts, financial data, and comparison tools that work without JavaScript.

Key Performance Metrics Available:

Daily, weekly, monthly, and yearly returns
52-week high and low prices
Market capitalization and valuation ratios
Financial health and profitability metrics
Dividend history and yield information

Performance & Financial Health Analysis: Ocular Therapeutix vs BridgeBio Pharma

Metric	OCUL	BBIO
Market Information
Market Cap i	$2.11B	$9.58B
Market Cap Category	Mid cap	Mid cap
10 Day Avg. Volume i	2,189,968	1,945,004
90 Day Avg. Volume i	2,179,529	2,637,425
Last Close	$12.30	$49.08
52 Week Range	$5.78 - $12.91	$21.72 - $51.86
% from 52W High	-4.73%	-5.36%
All-Time High	$44.19 (Mar 23, 2015)	$73.50 (Feb 08, 2021)
% from All-Time High	-72.17%	-33.22%
Growth Metrics
Quarterly Revenue Growth	-0.18%	50.00%
Quarterly Earnings Growth	-0.18%	50.00%
Financial Health
Profit Margin (TTM) i	0.91%	0.98%
Operating Margin (TTM) i	-5.03%	-1.21%
Return on Equity (TTM) i	-0.63%	0.37%
Debt to Equity (MRQ) i	25.15	-1.04
Cash & Liquidity
Book Value per Share (MRQ)	$1.77	$-9.35
Cash per Share (MRQ)	$2.25	$3.96
Operating Cash Flow (TTM) i	$-175,896,992	$-655,808,000
Levered Free Cash Flow (TTM) i	$-115,412,872	$-297,633,248
Dividends
Last 12-Month Dividend Yield i	N/A	N/A
Last 12-Month Dividend i	N/A	N/A

Valuation & Enterprise Metrics Analysis: Ocular Therapeutix vs BridgeBio Pharma

Metric	OCUL	BBIO
Price Ratios
P/E Ratio (TTM) i	-9.69	-17.12
Forward P/E i	-11.90	-16.38
PEG Ratio i	-0.19	-0.12
Price to Sales (TTM) i	37.28	40.63
Price to Book (MRQ) i	6.86	-5.28
Market Capitalization
Market Capitalization i	$2.11B	$9.58B
Enterprise Value i	$1.83B	$10.71B
Enterprise Value Metrics
Enterprise to Revenue i	32.26	45.43
Enterprise to EBITDA i	-7.70	-17.18
Risk & Other Metrics
Beta i	1.49	1.23
Book Value per Share (MRQ) i	$1.77	$-9.35

Financial Statements Comparison: Ocular Therapeutix vs BridgeBio Pharma

Financial Metrics

Loading Financial Charts...

Revenue

EBITDA

Shareholders Equity

Operating Margin

Free Cash Flow

Long Term Debt

Profit Margin

Current Ratio

Operating Cash Flow

Income Statement (MRQ)

Metric (MRQ)	OCUL	BBIO
Revenue/Sales i	$13.46M	$116.63M
Cost of Goods Sold i	$1.94M	$2.64M
Gross Profit i	$11.52M	$113.99M
Research & Development i	$51.08M	$111.43M
Operating Income (EBIT) i	$-67.64M	$-103.80M
EBITDA i	$-63.16M	$-104.46M
Pre-Tax Income i	$-67.81M	$-169.61M
Income Tax i	N/A	N/A
Net Income (Profit) i	$-67.81M	$-169.61M

Balance Sheet & Liquidity Metrics (MRQ)

Metric (MRQ)	OCUL	BBIO
Cash & Equivalents i	$349.68M	$540.60M
Total Current Assets i	$387.69M	$695.17M
Total Current Liabilities i	$37.93M	$152.11M
Long-Term Debt i	$74.07M	$1.85B
Total Shareholders Equity i	$265.93M	$-1.64B
Retained Earnings i	$-955.14M	$-3.26B
Property, Plant & Equipment i	$16.61M	$13.86M

Cash Flow Statement Comparison (MRQ)

Metric (MRQ)	OCUL	BBIO
Operating Cash Flow i	$-59.74M	$-215.45M
Capital Expenditures i	$-1.12M	$0
Free Cash Flow i	$-56.48M	$-200.83M
Debt Repayment i	N/A	$-459.00M
Common Stock Repurchase i	N/A	$-50.05M

Short Interest & Institutional Ownership Analysis

Metric	OCUL	BBIO
Shares Short i	12.83M	18.52M
Short Ratio i	6.08	7.46
Short % of Float i	0.07%	0.16%
Average Daily Volume (10 Day) i	2,189,968	1,945,004
Average Daily Volume (90 Day) i	2,179,529	2,637,425
Shares Outstanding i	157.75M	190.04M
Float Shares i	145.32M	151.20M
% Held by Insiders i	0.03%	0.05%
% Held by Institutions i	0.91%	1.02%

Dividend Analysis & Yield Comparison: Ocular Therapeutix vs BridgeBio Pharma

Metric	OCUL	BBIO
Last 12-Month Dividend i	N/A	N/A
Last 12-Month Dividend Yield i	N/A	N/A
3-Year Avg Annual Dividend i	N/A	N/A
3-Year Avg Dividend Yield i	N/A	N/A
3-Year Total Dividends i	N/A	N/A
Ex-Dividend Date	N/A	N/A

Ocular Therapeutix [OCUL] vs BridgeBio Pharma [BBIO] Detailed Stock Comparison